UA80679C2 - Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists - Google Patents
Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists Download PDFInfo
- Publication number
- UA80679C2 UA80679C2 UA2003109180A UA2003109180A UA80679C2 UA 80679 C2 UA80679 C2 UA 80679C2 UA 2003109180 A UA2003109180 A UA 2003109180A UA 2003109180 A UA2003109180 A UA 2003109180A UA 80679 C2 UA80679 C2 UA 80679C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antagonist
- methyl
- treatment
- application according
- single dose
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 7
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 6
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 239000005557 antagonist Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 5
- -1 antid Chemical compound 0.000 claims description 4
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 claims description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229950011372 teverelix Drugs 0.000 claims description 2
- BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 159000000021 acetate salts Chemical group 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 239000000174 gluconic acid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80679C2 true UA80679C2 (en) | 2007-10-25 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2003109180A UA80679C2 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (de) |
| EP (1) | EP1392348B1 (de) |
| JP (1) | JP2004529207A (de) |
| KR (1) | KR20040000446A (de) |
| CN (1) | CN1317030C (de) |
| AT (1) | ATE400287T1 (de) |
| AU (1) | AU2002310788B2 (de) |
| BG (1) | BG108339A (de) |
| BR (1) | BR0209290A (de) |
| CA (1) | CA2444876A1 (de) |
| CZ (1) | CZ20033167A3 (de) |
| DE (1) | DE60227507D1 (de) |
| DK (1) | DK1392348T3 (de) |
| ES (1) | ES2307760T3 (de) |
| HU (1) | HUP0400067A2 (de) |
| IL (1) | IL156777A0 (de) |
| MX (1) | MXPA03008666A (de) |
| NO (1) | NO20034322D0 (de) |
| NZ (1) | NZ544417A (de) |
| PL (1) | PL362319A1 (de) |
| PT (1) | PT1392348E (de) |
| RU (1) | RU2319501C2 (de) |
| SI (1) | SI1392348T1 (de) |
| SK (1) | SK14512003A3 (de) |
| UA (1) | UA80679C2 (de) |
| WO (1) | WO2002102401A1 (de) |
| ZA (1) | ZA200305326B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| AU7102201A (en) * | 2000-07-05 | 2002-01-14 | Yamanouchi Pharma Co Ltd | Propane-1,3-dione derivatives |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| EP1752452A4 (de) * | 2004-06-04 | 2010-07-14 | Astellas Pharma Inc | Propan-1,3-dionderivat und dessen salz |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| WO2006071274A2 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
| RU2404973C2 (ru) * | 2005-03-31 | 2010-11-27 | Астеллас Фарма Инк. | Производное соединение пропан-1,3-диона или его соль |
| US8642598B2 (en) * | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2009039983A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009043441A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | D-ala-gln-octadecyl ester as a therapeutic agent |
| EP2095818A1 (de) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Verwendung von LHRH-Antagonisten in nicht-kastrierenden Dosen |
| EP2307040B1 (de) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Gnrh und sexhormone zur behandlung von viruserkrankungen, insbesondere hiv/aids |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (de) * | 2018-04-26 | 2019-10-30 | LifeArc | Zusammensetzung zur behandlung einer oder mehrerer östrogenvermittelter krankheiten |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| DE19911771B4 (de) | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| WO2000069859A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| ES2249302T3 (es) * | 1999-10-15 | 2006-04-01 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados. |
| WO2001078780A1 (en) | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| AU7102201A (en) | 2000-07-05 | 2002-01-14 | Yamanouchi Pharma Co Ltd | Propane-1,3-dione derivatives |
-
2002
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 EP EP02735312A patent/EP1392348B1/de not_active Expired - Lifetime
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322D0/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1392348B1 (de) | 2008-07-09 |
| KR20040000446A (ko) | 2004-01-03 |
| CN1317030C (zh) | 2007-05-23 |
| CA2444876A1 (en) | 2002-12-27 |
| ATE400287T1 (de) | 2008-07-15 |
| IL156777A0 (en) | 2004-02-08 |
| JP2004529207A (ja) | 2004-09-24 |
| EP1392348A1 (de) | 2004-03-03 |
| NO20034322L (no) | 2003-09-26 |
| ZA200305326B (en) | 2003-07-30 |
| HK1072000A1 (en) | 2005-08-12 |
| MXPA03008666A (es) | 2004-10-15 |
| ES2307760T3 (es) | 2008-12-01 |
| RU2319501C2 (ru) | 2008-03-20 |
| CN1575185A (zh) | 2005-02-02 |
| WO2002102401A1 (en) | 2002-12-27 |
| NO20034322D0 (no) | 2003-09-26 |
| CZ20033167A3 (cs) | 2004-08-18 |
| DE60227507D1 (de) | 2008-08-21 |
| RU2003134949A (ru) | 2005-02-10 |
| US7288517B2 (en) | 2007-10-30 |
| US20020177556A1 (en) | 2002-11-28 |
| SK14512003A3 (sk) | 2004-08-03 |
| AU2002310788B2 (en) | 2007-04-05 |
| PL362319A1 (en) | 2004-10-18 |
| NZ544417A (en) | 2008-03-28 |
| SI1392348T1 (sl) | 2008-12-31 |
| DK1392348T3 (da) | 2008-09-29 |
| HUP0400067A2 (hu) | 2004-04-28 |
| BR0209290A (pt) | 2004-07-13 |
| BG108339A (bg) | 2004-11-30 |
| PT1392348E (pt) | 2008-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002310788B2 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| JP2006512417A5 (de) | ||
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| JP2023500032A5 (de) | ||
| JP5409602B2 (ja) | 慢性疼痛の治療におけるジミラセタムの使用 | |
| KR20240033207A (ko) | 체지방 과다의 치료적 또는 미용적 치료를 위한 nk-3 수용체 길항제 | |
| DE69927705T2 (de) | Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse | |
| US20240285603A1 (en) | Compositions and methods for intrathecal administration of mcoppb for pain relief | |
| CN1886136A (zh) | 治疗 | |
| EP3134417B1 (de) | Niedermolekulare analoga von e4orf1 | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| US10632132B2 (en) | Methods for treating heart transplant rejection | |
| US12268679B1 (en) | Compositions and methods for epidural administration of MCOPPB for pain relief | |
| KR102308146B1 (ko) | 항암제에 의해 유도되는 이질통의 예방 또는 치료용 조성물 및 이를 이용한 치료방법 | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| ZA200308632B (en) | The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis. | |
| HK1235406A1 (en) | Small molecule analogs of e4orf1 | |
| HK1235406B (en) | Small molecule analogs of e4orf1 | |
| EA044055B1 (ru) | Применение антагониста рецептора нейрокинина-3 (nk-3) для повышения уровней циркулирующего лептина у пациентов |